The CEO of Propanc Biopharma will attend the 43rd meeting of the European Organization for Research and Treatment of Cancer (EORTC), December 15-17

Melbourne, Australia–(BUSINESS WIRE)–Propanc Biopharma, Inc. (OTC Pink: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel cancer treatments for patients with recurrent and metastatic cancer, today announced that Mr. James Nathanielsz, CEO of Propanc, will take part in the 43rd Meeting of the European Organization for Research and Treatment of Cancer (EORTC), Pharmacology and Molecular Mechanisms (PAMM) group. Professor Perán, Joint Principal Investigator of Propanc, will also present at the EORTC-PAMM annual meeting to be held in Florence, Italy, from December 15-17. Topics covered will be innovation and the application of pharmacological knowledge to the discovery and development of anti-cancer drugs, with particular focus on innovative and advanced drugs and their mechanisms of action, pharmacometrics and clinical application in oncology. Prof. Perán, supported by Ms. Belén Toledo Cutillas MSc and Mr. Aitor González from Prof. Perán’s laboratory at the University of Jaén, will present findings on the anticancer effects of the company’s lead product candidate, PRP, the effects on the tumor microenvironment and scaling up of recombinant protein production for a clinical rescue compound for PRP.

The EORTC is a prestigious and globally recognized organization with significant resources and reach. Mr. Nathanielsz looks forward to attending the 43rd EORTC-PAMM meeting with the universities of Jaén and Granada, within the framework of the joint research collaboration project. Propanc’s goal is to produce a long-term, non-toxic therapy for the treatment and prevention of metastatic cancer in solid tumors by targeting and eradicating cancer stem cells, and as an adjunctive therapy to pre-treat resistant tumors. .

“Attending the EORTC-PAMM meeting provides an exciting opportunity to meet scientific experts and clinical investigators who are at the forefront of cancer drug development, which provides an opportunity to discuss recent scientific findings from our PRP, R&D project and its potential clinical applications as a pretreatment with existing innovative cancer therapies,” said Mr. Nathanielsz, CEO of Propanc. “Professor Perán discovered how PRP treats and prevents metastatic cancer by targeting and eradicating cancer stem cells through differentiation (backtracking), so that they become benign and no longer malignant, without affecting healthy cells. She is also studying the effects of PRP on the tumor microenvironment, where resistant tumors become responsive to standard therapies, after treatment with PRP. We are excited to present our research with Professor Perán as we investigate future clinical applications of PRP in controlled human studies.

The mission of the EORTC is to increase the survival and quality of life of people by testing new therapeutic strategies based on existing drugs, surgery and radiotherapy. The EORTC also contributes to the development of new drugs and approaches in partnership with the pharmaceutical industry and in the interest of patients. The EORTC research network consists of more than 5,500 collaborators from all disciplines involved in cancer treatment and research at more than 930 institutions in 27 countries. His research spans the spectrum, from translational and preclinical research to large prospective, multi-center Phase III clinical trials evaluating new cancer therapies.

Propanc is currently undertaking two joint research and collaboration projects with the universities of Jáen and Granada. The first project, POP1 (Proenzyme Optimization Project 1) Joint Research and Drug Discovery Program, is designed to produce a post-PRP clinical compound that targets metastatic cancer in solid tumors. The second is to study the effects of proenzyme therapy and the impact on the tumor microenvironment, which is essential for the development, invasion, metastatic spread and recurrence of solid tumors. This has potential implications for future clinical applications of PRP as a potential pretreatment for resistant tumors. According to Emergen Research, the global metastatic cancer market is expected to reach $111 billion by 2027. Propanc is undertaking these ambitious research projects in collaboration with the Universities of Jaén and Granada, led by Professors Perán and Juan Antonio Marchal MD, representing universities. , respectively, and Dr. Kenyon, MD, MB, ChB, scientific director of Propanc.

PRP is a mixture of two proenzymes, trypsinogen and chymotrypsinogen from the bovine pancreas administered by intravenous injection. A synergistic ratio of 1:6 inhibits the growth of most tumor cells. Examples include kidney, ovarian, breast, brain, prostate, colorectal, lung, liver, uterine, and skin cancers.

About the EORTC

As an independent, non-governmental, non-profit cancer research organization established under the laws of Belgium, its mission is to coordinate and conduct international translational and clinical research to improve the standard of cancer treatment for patients.

The EORTC ultimately aims to increase people’s survival and quality of life by testing new therapeutic strategies based on existing drugs, surgery and radiotherapy. The EORTC is also helping to develop new approaches with the pharmaceutical industry and for the benefit of patients.

In addition to its independence, the EORTC is recognized for its scientific and methodological rigor bringing robust data sets to physicians and patients for therapeutic improvement. The EORTC covers all disciplines in the fight against cancer. EORTC research leaves no one behind and is relevant to all patients, including patients with rare tumors and specific patient populations.

About Professor Macarena Perán

Professor Macarena Perán obtained a BS in Biology and an MSc in Biochemistry and Molecular Biology in 1996 from the University of Malaga, Spain. She joined the Department of Neuroscience at Durham University, UK, where she received a Marie Curie Fellowship and in 2000 was awarded a PhD. She returned to Spain and completed a postdoctoral program at the Faculty of Medicine of the University of Granada.

In 2005 and 2006, Macarena went to the University of Bath, UK, and was a short-term postdoctoral fellow in the Department of Biology and Biochemistry in Professor David Tosh’s laboratory, where she first studied the anti-cancer effects of proenzymes in collaboration with Propanc Biopharma Inc. Prof. Perán is Lecturer in Anatomy, University of Jaen, Spain and belongs to the Institute of Regenerative Medicine and Pathobiology (IBIMER).

About the University of Jaén:

The University of Jaén is among the Top 50 of the best young universities in the world according to THE (Times Higher Education). Likewise, the University of Jaén has been awarded the European Seal of Excellence EFQM 500+, the highest level of recognition awarded by the Excellence in Management Club, as an official representative of the European Foundation for Quality Management (EFQM) in Spain. It also stands out in the field of computer science, since the University of Jaén is among the 75 best universities in the world, according to the Academic Ranking of World Universities (ARWU) 2017.

The University of Jaén is repeatedly included in the top 4% of universities in the world, according to the Ranking Center for World University Rankings (CWUR), which annually collects the best and most valued thousand among more than 25,000 existing universities. In addition, it is the fourth Spanish university with the highest score in the International Student Satisfaction Ranking, published by the International Organization of Study Portals STERX, in its 2016 version.

About Propanc Biopharma, Inc.

Propanc Biopharma, Inc. (the “Company”) is developing a novel approach to prevent recurrence and metastasis of solid tumors using pancreatic proenzymes that target and eradicate cancer stem cells in patients with pancreatic, ovary and colorectal. For more information, please visit www.propanc.com.

The company’s new proenzyme therapy is based on the science that enzymes stimulate biological reactions in the body, particularly enzymes secreted by the pancreas. These pancreatic enzymes may represent the body’s main defense against cancer.

To view the Company’s “Mechanism of Action” video on its lead cancer product candidate, PRP, please click on the following link: http://www.propanc.com/news-media/video

Forward-looking statements

All statements other than statements of historical fact contained in this press release are “forward-looking statements”, which can often, but not always, be identified by the use of words such as “may”, “could”, ” will”, “probably result”, “should”, “should”, “estimate”, “plan”, “project”, “plan”, “intend”, “expect”, “anticipate” , “believe”, “seek”, “continue”, “target” or the negative of these terms or other similar expressions. These statements involve known and unknown risks, uncertainties and other factors, which may cause actual results, performance or achievements to differ materially from those expressed or implied by such statements. These factors include uncertainties about the Company’s ability to continue as a going concern in the absence of new debt or equity financing; the Company’s current dependence on significant debt financing which it is unable to repay in cash; the Company’s ability to successfully address material weaknesses in its internal controls; the Company’s ability to achieve research and development milestones as planned and within proposed budgets; the Company’s ability to control costs; the Company’s ability to obtain adequate new financing on reasonable terms; the Company’s ability to successfully initiate and complete clinical trials and its ability to successfully develop PRP, its lead product candidate; the Company’s ability to obtain and maintain patent protection; the Company’s ability to recruit employees and directors with accounting and financial expertise; the Company’s dependence on third parties for services; the Company’s dependence on key management; the impact of government regulations, including FDA regulations; the impact of any future litigation; the availability of capital; changes in economic conditions, competition; and other risks, including, but not limited to, those described in the Company’s periodic reports that are filed with the Securities and Exchange Commission and available on its website at http://www.sec.gov. These forward-looking statements speak only as of the date hereof, and the Company disclaims any obligation to update these statements except as required by law.

Aubrey L. Morgan